[ad_1]
The FDA approved the emergency use of Eli Lilly’s only drug that contains coronavirus antibodies to treat patients with mild or moderate COVID-19.
The “Daily Mail” newspaper said the drug will begin shipping immediately and will be assigned to states on a weekly basis based on case data provided to HHS.
The US government has signed a $ 375 million contract with Lilly for 300,000 doses of the drug, which can buy another 650,000 doses until the end of June.
Former President Trump had promised to make COVID-19 antibody treatments free to anyone in need, but how or if this is possible is unclear.
The newspaper said the United States Food and Drug Administration gave permission last night, Monday, for the emergency use of Eli Lilly’s experimental Corona COVID-19 antibody treatment, which was praised by the former President Donald Trump and pledged to make it freely available to all Americans.
The US agency explained that its license for emergency use was based on clinical trials that showed that the treatment, called bamlanivimab, reduced the need for hospitalization or emergency room visits for COVID-19 patients who are at high risk of develop the disease.
Early results indicate that it can help get rid of the coronavirus earlier and can reduce hospitalization for people with mild to moderate COVID-19.
And the US Food and Drug Administration approved its use in mild to moderate cases of the coronavirus, COVID-19, in adults and children over 12 years of age.
Leila said the drug will begin shipping immediately to the main AmerisourceBergen distributor.
Last month, the US government signed a $ 375 million deal with Lilly for 300,000 doses of the antibody drug to distribute over the next two months in the US. The government will have the option to buy another 650,000 doses until June 30.
The newspaper added that although Lilly did not specify the number of doses currently prepared, it had previously stated that 100,000 doses of its antibody drug could be provided within days of emergency US approval.
He confirmed that Bamlanivimab will be assigned to the United States on a weekly basis, based on the number of confirmed cases recorded in the Department of Health and Human Services (HHS) data for each jurisdiction over the previous seven days.
And the newspaper added that two weeks ago, Lilly revealed that his treatment with antibodies against the coronavirus almost completely reduces viral loads in patients with mild or moderate coronavirus to zero and reduces their risk of hospitalization.
The researchers found that patients with mild and moderate disease who received a high dose of the LY-CoV555 antibody, also known as bamlanivimab, had 3.4 times fewer viral loads than those who received a placebo.
Furthermore, those who received any dose of LY-CoV555 were 4 times less likely to be hospitalized.
